Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere wi

Trial Details

NCT ID
NCT05168163
Phase
PHASE2
Sponsor
Academic and Community Cancer Research United
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Atezolizumab
  • Cabozantinib
  • Lenvatinib
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Weston, Florida, United States|26.10037,-80.39977
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Urbana, Illinois, United States|40.11059,-88.20727

Key Eligibility Criteria

  • Provide written informed consent =\< 28 days prior to randomization
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
  • NOTE: During the Active Monitoring Phase of a study (i.e., active treatment and clinical follow-up), participants must be willing to return to the …
  • Age \>= 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →